12/09/2024
Overcoming Analytical Challenges in Liraglutide & Semaglutide Analysis
Glucagon-like peptide-1 (GLP-1) analogues, including Liraglutide and Semaglutide, have emerged as key therapeutic agents for the management of type II diabetes mellitus and obesity. However, the accurate quantification of these peptides in biological matrices presents significant analytical challenges. These challenges stem from the large molecular size of the peptides, their suboptimal ionization efficiency in mass spectrometry, and inherent issues related to sensitivity and sample preparation. The incorporation of a fatty acid moiety in these peptides further exacerbates these difficulties by increasing hydrophobicity and non-specific binding.
The work presented at the 10th EBF Young Scientist Symposium highlights the analytical challenges of developing UPLC/MS/MS methodologies for the extraction and quantification of Liraglutide and Semaglutide in plasma, while also outlining the strategies employed to solve them.
You may find below the poster for your ready reference:
MORE NEWS
Overcoming Matrix Effects in the Analysis of Lipophilic Compounds
At the 10th EBF Young Scientist Symposium, we highlighted the complexities of analysing Fucoxanthin derivatives and demonstrated how innovative approaches, such as 2D Chromatography, can overcome these obstacles.
Anapharm Bioanalytics Recognized as an Innovative SME
We are thrilled to announce that Anapharm Bioanalytics has recently been officially recognized as an Innovative SME (PYME Innovadora) by the Spanish Ministry of Science and Innovation.
Anapharm Bioanalytics Brazilian ANVISA Certificate Renewal
Anapharm Bioanalytics is proud to announce that it has recently renewed its ANVISA (Brazil) certification which is now valid until February 26th, 2026.